(3Z)-3-{2-[(4E)-1-[(3E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylcyclohexan-1-ol

• ChemBase编号: 941
• 分子式: C28H46O
• 平均质量: 398.66424
• 单一同位素质量: 398.35486609
• SMILES: OC1C/C(=C/C=C\2/C3C(C(CC3)C(C)/C=C/C(C(C)C)C)(CCC2)C)/C(CC1)C
• Canonical SMILES: OC1CCC(/C(=C\C=C\2/CCCC3(C2CCC3C(/C=C/C(C(C)C)C)C)C)/C1)C
• InChI: InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13-
• InChIKey: ILYCWAKSDCYMBB-AAGLSAJLSA-N

名称和登记号

名称

• IUPAC标准名: (3Z)-3-{2-[(4E)-1-[(3E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylcyclohexan-1-ol; 3-{2-[1-(5,6-dimethylhept-3-en-2-yl)-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylcyclohexan-1-ol
• IUPAC传统名: dihydrotachysterol; 3-{2-[1-(5,6-dimethylhept-3-en-2-yl)-7a-methyl-hexahydro-1H-inden-4-ylidene]ethylidene}-4-methylcyclohexan-1-ol
• 商标名: Antitanil; Calcamine; DHT Intensol; Dichystrolum; Dihydral; Dygratyl; Hytakerol; Parterol; Tachystin
• 别名: Vitamin D4; Dihydrotachysterol; Dihydrotachysterol; DIHYDROTACHYSTEROL, CRYST

登记号

• CAS号: 67-96-9
• PubChem SID: 160964404
• PubChem CID: 5281010

理论计算性质

JChem

• Acid pKa: 18.296175
• 质子受体: 1
• 质子供体: 1
• LogD (pH = 5.5): 7.398204
• LogD (pH = 7.4): 7.398204
• Log P: 7.398204
• 摩尔折射率: 129.1122 cm^3
• 极化性: 50.09825 Å^3
• 极化表面积: 20.23 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 7.86
• LOG S: -6.5
• 溶解度: 1.25e-04 g/l

分子性质

理化性质

• 疏水性(logP): 7.5

详细说明

MP Biomedicals - 05213006

MP Biomedicals Rare Chemical collection

DrugBank - DB01070

• Drug Groups: approved
• Description: A vitamin D that can be regarded as a reduction product of vitamin D2. [PubChem]
• Indication: Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
• Pharmacology: Dihydrotachysterol is hydroxylated in the liver to 25-hydroxydihydrotachysterol, which is the major circulating active form of the drug. It does not undergo further hydroxylation by the kidney and therefore is the analogue of 1, 25-dihydroxyvitamin D. Dihydrotachysterol is effective in the elevation of serum calcium by stimulating intestinal calcium absorption and mobilizing bone calcium in the absence of parathyroid hormone and of functioning renal tissue. Dihydrotachysterol also increases renal phosphate excretion.
• Toxicity: Toxicity associated with dihydrotachysterol is similar to that seen with large doses of vitamin D.
• Affected Organisms: Humans and other mammals
• Protein Binding: >99%
• References: DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. [Pubmed] ; Bosch R, Thijssen JH, Duursma SA: Action and metabolism of dihydrotachysterol2. J Steroid Biochem. 1987;27(4-6):829-36. [Pubmed] ; Pierides AM: Pharmacology and therapeutic use of vitamin D and its analogues. Drugs. 1981 Apr;21(4):241-56. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. Pubmed
• Bosch R, Thijssen JH, Duursma SA: Action and metabolism of dihydrotachysterol2. J Steroid Biochem. 1987;27(4-6):829-36. Pubmed
• Pierides AM: Pharmacology and therapeutic use of vitamin D and its analogues. Drugs. 1981 Apr;21(4):241-56. Pubmed